Vyome Holdings, Inc. (NASDAQ:HIND) Short Interest Update

Vyome Holdings, Inc. (NASDAQ:HIND) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 76,872 shares, a growth of 272.0% from the November 30th total of 20,666 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average daily volume of 93,344 shares, the days-to-cover ratio is currently 0.8 days. Based on an average daily volume of 93,344 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HIND shares. Maxim Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Vyome in a research note on Thursday, October 2nd. Weiss Ratings reissued a “sell (e-)” rating on shares of Vyome in a report on Monday. Citigroup raised Vyome to a “buy” rating in a research note on Thursday, October 2nd. Finally, Wall Street Zen upgraded Vyome from a “sell” rating to a “hold” rating in a research report on Thursday, October 9th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Vyome currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Vyome Price Performance

Vyome stock traded down $0.03 during trading on Friday, hitting $3.73. The company’s stock had a trading volume of 16,372 shares, compared to its average volume of 357,392. The stock has a fifty day moving average price of $5.02. Vyome has a 1-year low of $3.57 and a 1-year high of $519.00. The stock has a market capitalization of $21.04 million, a PE ratio of -0.03 and a beta of 1.21.

Vyome (NASDAQ:HIND) last posted its quarterly earnings results on Friday, November 14th. The company reported ($3.12) EPS for the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 423.39%. The business had revenue of $0.04 million during the quarter.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.